Entacapone
Back to searchMolecule Structure
Scientific Name
Entacapone
Description of the Drug
Entacapone is a selective reversible catechol-O-methyltransferase inhibitor for the treatment of Parkinson’s disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00494
http://www.drugbank.ca/drugs/DB00494
Brand Name(s)
Comtan, Comtess, Entacapone
Company Owner(s)
Sunshine Lake Pharma Co Ltd, Ajanta Pharma Ltd, Alembic Pharmaceuticals Ltd, Orion Pharma, Macleods Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Wockhardt Ltd, Mylan Pharmaceuticals Inc, Atlantide Pharmaceuticals Ag
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Catechol O-methyltransferase | SINGLE PROTEIN | INHIBITOR | CHEMBL2023 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL34504 | |
| PharmGKB | PA164748726 | |
| Human Metabolome Database | HMDB0012226 | |
| DrugBank | DB00494 | |
| PubChem: Thomson Pharma | 14776335 | |
| PubChem | 5281081 | |
| LINCS | LSM-43240 | |
| PDBe | PD9 | |
| BindingDB | 50108879 | |
| EPA CompTox Dashboard | DTXSID5046439 | |
| DrugCentral | 1018 | |
| Brenda | 17740 | |
| ChemicalBook | CB5726435 | |
| Guide to Pharmacology | 6647 | |
| rxnorm | COMTAN | ENTACAPONE |
| PubChem: Drugs of the Future | 12014660 | |
| KEGG Ligand | C07943 | |
| ChEBI | 4798 | |
| ZINC | ZINC000035342787 |
